Filtered By:
Condition: Bleeding
Education: Academia

This page shows you your search results in order of relevance. This is page number 20.

Order by Relevance | Date

Total 422 results found since Jan 2013.

Clinical Outcomes of Ticagrelor in Korean Patients with Acute Myocardial Infarction without High Bleeding Risk
CONCLUSIONS: The bleeding risk of ticagrelor was attenuated in Korean patients with AMI without HBR. Appropriate patient selection could reduce in-hospital bleeding complications associated with ticagrelor in Korean patients with AMI who underwent successful PCI.PMID:34725976 | DOI:10.3346/jkms.2021.36.e268
Source: Journal of Korean Medical Science - November 2, 2021 Category: Biomedical Science Authors: Keun-Ho Park Myung Ho Jeong Hyun Kuk Kim Young-Jae Ki Sung Soo Kim Dong-Hyun Choi Young-Youp Koh Youngkeun Ahn Hyo-Soo Kim Hyeon-Cheol Gwon Seung-Woon Rha Jin-Yong Hwang KAMIR-NIH registry investigators Source Type: research

White blood cell count and clinical outcomes after left main coronary artery revascularization: insights from the EXCEL trial
Conclusion There was no association between baseline WBCc and 30-day or 5-year clinical outcomes after PCI or CABG. The absence of a clear incremental increase in events with increasing WBCc in the current analysis indicates that WBCc should not routinely be used as a prognostic marker or to guide revascularization decisions in patients with LMCAD.
Source: Coronary Artery Disease - December 9, 2021 Category: Cardiology Tags: PCI Source Type: research

Comparison of Net Clinical Benefit Between Clopidogrel and Ticagrelor Following Percutaneous Coronary Intervention in Patients in China With Acute Coronary Syndrome
ConclusionIn Chinese ACS patients who underwent PCI with second-generation DESs, outpatient use of clopidogrel dual antiplatelet therapy (DAPT) was associated with reduction in NACCE and bleeding.
Source: Advances in Therapy - December 13, 2021 Category: Drugs & Pharmacology Source Type: research

Prasugrel-based De-Escalation of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients With STEMI
CONCLUSIONS: Prasugrel dose de-escalation reduced the rate of NACE and bleeding, without increasing the rate of ischemic events in NSTE-ACS patients but not in STEMI patients.PMID:35129316 | DOI:10.4070/kcj.2021.0293
Source: Korean Circulation Journal - February 7, 2022 Category: Cardiology Authors: You-Jeong Ki Bong Ki Lee Kyung Woo Park Jang-Whan Bae Doyeon Hwang Jeehoon Kang Jung-Kyu Han Han-Mo Yang Hyun-Jae Kang Bon-Kwon Koo Dong-Bin Kim In-Ho Chae Keon-Woong Moon Hyun Woong Park Ki-Bum Won Dong Woon Jeon Kyoo-Rok Han Si Wan Choi Jae Kean Ryu Myu Source Type: research